Helene Derumeaux
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Helene Derumeaux has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Alain Grand
UMR 1027, University of Toulouse III, Toulouse, F-31059, France
1 shared publication - Bruno Vellas
IHU HealthAge & WHO Collaborating Center for Frailty, Clinical & Geroscience Research, and Geriatric Training, Toulouse University Hospital, La Grave, 31 059 Toulouse, France
1 shared publication - Guillaume Moulis
Department of Internal Medicine Toulouse University Hospital Toulouse France
1 shared publication - Julien Maquet
Department of Internal Medicine, Toulouse University Hospital, Toulouse, France
1 shared publication - Laura Ferlicoq
Department of Medical Information, University Hospital of Toulouse, Toulouse, F-31059, France
1 shared publication - Laurent Molinier
Health Economic Unit of the University Hospital of Toulouse, Toulouse, France
1 shared publication
Latest Publications
- 1 September 2020
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 79, 136-138
Validation of hemolytic anemia discharge diagnosis codes in the French hospital database
- 1 September 2020
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 79, 136-138
Validation of hemolytic anemia discharge diagnosis codes in the French hospital database
- Open Access
- 11 September 2012
- Published by Springer Nature in Health Economics Review
- Vol. 2 (1) , 18
Methodological considerations in cost of illness studies on Alzheimer disease
Cost-of-illness studies (COI) can identify and measure all the costs of a particular disease, including the direct, indirect and intangible dimensions. They are intended to provide estimates about the economic impact of costly disease. Alzheimer disease (AD) is a relevant example to review cost of illness studies because of its costliness.The aim of this study was to review relevant published cost studies of AD to analyze the method used and to identify which dimension had to be improved from a methodological perspective. First, we described the key points of cost study methodology. Secondly, cost studies relating to AD were systematically reviewed, focussing on an analysis of the different methods used. The methodological choices of the studies were analysed using an analytical grid which contains the main methodological items of COI studies. Seventeen articles were retained. Depending on the studies, annual total costs per patient vary from $2,935 to $52, 954. The methods, data sources, and estimated cost categories in each study varied widely. The review showed that cost studies adopted different approaches to estimate costs of AD, reflecting a lack of consensus on the methodology of cost studies. To increase its credibility, closer agreement among researchers on the methodological principles of cost studies would be desirable.
- 11 September 2012
- Published by Springer Nature in Health Economics Review
- Vol. 2 (1) , 18
Open AccessMethodological considerations in cost of illness studies on Alzheimer disease
Cost-of-illness studies (COI) can identify and measure all the costs of a particular disease, including the direct, indirect and intangible dimensions. They are intended to provide estimates about the economic impact of costly disease. Alzheimer disease (AD) is a relevant example to review cost of illness studies because of its costliness.The aim of this study was to review relevant published cost studies of AD to analyze the method used and to identify which dimension had to be improved from a methodological perspective. First, we described the key points of cost study methodology. Secondly, cost studies relating to AD were systematically reviewed, focussing on an analysis of the different methods used. The methodological choices of the studies were analysed using an analytical grid which contains the main methodological items of COI studies. Seventeen articles were retained. Depending on the studies, annual total costs per patient vary from $2,935 to $52, 954. The methods, data sources, and estimated cost categories in each study varied widely. The review showed that cost studies adopted different approaches to estimate costs of AD, reflecting a lack of consensus on the methodology of cost studies. To increase its credibility, closer agreement among researchers on the methodological principles of cost studies would be desirable.